We found that a risk score based on a novel panel of three metabolite-based biomarkers plus NT-proBNP outperformed commonly used traditional prognostic models for predicting cardiovascular mortality in elderly ambulatory CHF patients. This evidence concerns the gene NPPB and congestive heart failure.